acrimal gland botulinum toxin injection for chronic epiphora in patients with anatomical or functional nasolacrimal duct obstruction: A randomised, double-blinded, placebo-controlled, crossover trial using subjective endpoints.
- Conditions
- Anatomical nasolacrimal duct obstructionFunctional nasolacrimal duct obstructionChronic epiphoraEye - Diseases / disorders of the eye
- Registration Number
- ACTRN12616000039482
- Lead Sponsor
- Dr Kenneth Chan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 50
Documented diagnosis of either NLDO or FNLDO (or both) as diagnosed by dye disappearance test, lacrimal lavage and Jones test;
- Pre-treatment Munk Score of 4 or 5 (moderate to severe symptoms); and
- Chronic epiphora for 6 months or more.
- Age under 18 years;
- Unable to provide informed consent;
- Previous botulinum toxin treatment of any kind; or
- Any of the following conditions:
Punctal ectropion; horizontal lid laxity >8mm; tear break-up time <7 seconds; signs of superficial punctate keratopathy on slit-lamp examination with Fluorescein staining; acute or chronic conjunctivitis; acute or chronic corneal ulcer; spastic or cicatricial entropion; trichiasis; thyroid eye disease; history of allergic rhinitis with positive response to intranasal steroid; or documented dacryocystitis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method